This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
Diagnosed as local recurrence ± regional recurrence after ≥1 year of radical treatment;
Not suitable for surgery;
Newly histologic diagnosis of NPC (WHO II/III);
Clinical stage rII-IVa (AJCC/UICC 8th);
Treated with anti-tumor Chinese medicine treatment;
Have recurrence with local necrosis;
Have ≥G3 late toxicities, except for skin, subcutaneous tissue or mucosa;
Unexplained fever > 38.5 ℃, except for tumor fever;